Instrument Inactif

Communiqués Aimmune Therapeutics, Inc.

Actions

AIMT

US00900T1079

Recherche biotechnologique et médicale

Communiqués

22/01/21	Aimmune Therapeutics : European Commission approves Aimmune's PALFORZIA as first-ever treatment for peanut allergy in the EU	AQ
05/01/21	Aimmune Therapeutics : European Commission approves first treatment for peanut allergy	AQ
22/12/20	Aimmune Therapeutics : European Commission approves Aimmune's PALFORZIA as first-ever treatment for peanut allergy in the EU	AQ
21/12/20	Aimmune Therapeutics : European Commission Approves Aimmune’s PALFORZIA® as First-Ever Treatment for Peanut Allergy in the EU	BU
19/10/20	AIMMUNE THERAPEUTICS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers (form 8-K)	AQ
19/10/20	Aimmune Therapeutics : Receives Positive CHMP Opinion on PALFORZIA for the Treatment of Patients with Peanut Allergy in Europe	AQ
15/10/20	Aimmune Therapeutics : Nestle Completes Acquisition of Aimmune Therapeutics	AQ
13/10/20	Aimmune Therapeutics : Nestle announces results of tender offer for Aimmune Therapeutics Inc.	AQ
15/09/20	Aimmune Therapeutics : Nestle commences tender offer for Aimmune Therapeutics Inc	AQ
14/09/20	Aimmune Therapeutics : Nestlé commences tender offer for Aimmune Therapeutics, Inc.	PR
05/09/20	AIMMUNE INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Aimmune Therapeutics Inc. - AIMT	BU
01/09/20	Aimmune Therapeutics : Nestlé Health Science to acquire Aimmune Therapeutics for $2.6 billion	AQ
01/09/20	Aimmune Therapeutics : Nestle to acquire Aimmune Therapeutics	AQ
01/09/20	Aimmune Therapeutics : Enters Definitive Agreement with Societes des Produits Nestle S.A. Part of Nestle Health Science	AQ
31/08/20	(AIMT) Alert: Johnson Fistel Investigates Proposed Sale of Aimmune Therapeutics; Is $34.50 a Fair Price?	PR
31/08/20	AIMMUNE THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
31/08/20	Aimmune Therapeutics : Enters Definitive Agreement with Sociétés des Produits Nestlé S.A., Part of Nestlé Health Science	BU
25/08/20	Aimmune Therapeutics : Largest European Qualitative Study on Peanut Allergy Highlights Negative Impact of Avoidance and Fear of Accidental Peanut Allergy Reactions	AQ
24/08/20	Aimmune Therapeutics : Largest European Qualitative Study on Peanut Allergy Highlights Negative Impact of Avoidance and Fear of Accidental Peanut Allergy Reactions on Allergic Individuals and Their Caregivers	BU
10/08/20	Aimmune Therapeutics : to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference	AQ
07/08/20	Aimmune Therapeutics : to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference	BU
31/07/20	AIMMUNE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
30/07/20	Aimmune Therapeutics: 2Q Earnings Snapshot	AQ
30/07/20	Aimmune Therapeutics : Announces Second Quarter 2020 Financial Results and Provides Recent Operational Highlights	BU
23/07/20	Aimmune Therapeutics : to Host Conference Call and Webcast to Discuss Second Quarter 2020 Financial Results and Recent Operational Highlights	BU